NIKKEI 225
37,308.04 -771.66 (-2.03%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
83.70 +0.97 (+1.17%) GOLD FUTURES
2,397.50 -0.50 (-0.02%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,250.04 +699.39 (+1.41%)
Roche Holding AG (0QQ6.IL)
| Previous close | 310.40 |
| Open | 312.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 309.20 - 313.40 |
| 52-week range | 309.20 - 389.76 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
What To Watch: Novo Nordisk
Novo Nordisk (NVO), the Danish drugmaker behind Ozempic & Wegovy has become a household name and one of Europe's most valuable companies. What To Watch focuses in on three key issues as Novo Nordisk reports 4th quarter earnings on January 25th: 1. Expansion: 3rd quarter results were music to investors ears with a 29% jump in sales to 8.4 billion dollars. The unprecedented off label sales of its diabetes drug Ozempic started a stampeded to keep up with demand & a global surge in counterfeits. Novo’s deal is worth up to 1 billion dollars with U.S. biotech startups and plans for expanding capacity will be watched with interest. 2. Competitors: Eli Lilly (LLY) is in hot pursuit though diabetes drug Mounjaro and with obesity drug Zepbound after FDA approval in November. Lilly also started a new website to connect patients seeking treatment with Telehealth providers. Then there is Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), & Astra Zeneca (AZN) all fighting for a piece of the pie. The battle is on for a share of the market that could be worth 100 billion dollars by the end of the decade. 3. Barriers: There are many hurdles for Novo Nordisk. For one, Medicare does not cover weight loss drugs & Novo has been lobbying Congress to release these restrictions. Some insurers are hesitant to cover or have strict prior authorization rules in place. Can Novo keep as much supply as Eli Lilly ramps up their production capacity? Lots to digest as we wait to see how one of the biggest stories in business news develops.
- Yahoo Finance
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.
- Yahoo Finance Video
How Roche aims to change the 'standard of care'
Speaking at the JPMorgan Healthcare Conference, Roche Pharmaceuticals (RHHBY) CEO Teresa Graham discusses the company's innovation focus and outlook with Yahoo Finance's Anjalee Khemlani. Graham says Roche has "defined itself as a company that follows innovation" across health care sectors. Currently, they see huge potential in the obesity drug space as analysts forecast the weight loss market reaching $100 billion within years. However, Roche hopes to expand cretinism beyond obesity into neurological disease applications. On dealmaking, Graham notes Roche pursues "groundbreaking science" that can "materially change the standard of care" for high unmet-need diseases. She stresses they remain open across therapeutic areas to back advances that drive health forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith
